title: [Targeted molecular therapies (except immunotherapy)].
abstract: Metastatic melanoma has been a very poor prognostic cancer with a median of survival between six to eight months. A lot of new therapies have been discovered these last years. Two types of treatment have emerged: immunotherapy and targeted therapy. Targeted therapies have been developed because of the discovery of new oncogenic mutations with a big impact of melanoma development. The efficacy is great with a high overall response and a good tolerance. However, most of patients escape in few months of targeted therapy. The sequence of drug using and their combination are the question for the next years.
authors.affiliation: Hôpital Saint-Louis, Service de dermatologie, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: jennifer.roux@sls.aphp.fr.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Roux
authors.affiliation: Hôpital Saint-Louis, Service de dermatologie, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Pages
authors.affiliation: Hôpital Saint-Louis, Service de dermatologie, 1, avenue Claude-Vellefaux, 75010 Paris, France.
authors.forename: Céleste
authors.initials: C
authors.lastname: Lebbé
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D048728:MAP Kinase Kinase Kinase 1 / Q000037:antagonists & inhibitors; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary*; D058990:Molecular Targeted Therapy / Q000379:methods*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D010091:Oximes / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D011728:Pyridones / Q000627:therapeutic use; D011744:Pyrimidinones / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D013449:Sulfonamides / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D009363:Neoplasm Proteins; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; C560077:trametinib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D048728:MAP Kinase Kinase Kinase 1; C561627:dabrafenib
keywords: BRAF inhibitor; MEK inhibitor; cKIT inhibitor; inhibiteur de BRAF; inhibiteur de MEK; inhibiteur de cKIT; metastatic melanoma; métastatique